

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin)
Recombinant Antibody
Catalog # APR10096****Specification**

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) - Product Information

| | |
|-------------------|------------------------|
| Application | FC, E, FTA |
| Primary Accession | P32970 |
| Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 146.1 KDa |

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) - Additional Information**Target/Specificity**

TNFSF7 / CD27L / CD70

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

MMAF

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) - Protein Information**Name** CD70 ([HGNC:11937](#))**Function**

Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed:28011863, PubMed:28011864, PubMed:8387892). The CD70-CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed:28011863, PubMed:28011864).


Cellular Location

Cell membrane; Single-pass type II membrane protein


Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) - Images

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) is more than 99.29%, determined by SEC-HPLC.